JG
RYTM icon

Joel Greenblatt’s Rhythm Pharmaceuticals RYTM Stock Holding History

Joel Greenblatt’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Buy
5,516
+668
+14% +$60.4K ﹤0.01% 1466
2026
Q1 		$422K Sell
4,848
-3
-0.1% -$292 ﹤0.01% 1528
2025
Q4 		$519K Sell
4,851
-4
-0.1% -$424 ﹤0.01% 1426
2025
Q3 		$490K Buy
4,855
+4
+0.1% +$371 ﹤0.01% 1384
2025
Q2 		$307K Buy
4,851
+101
+2% +$6.18K ﹤0.01% 1453
2025
Q1 		$252K Sell
4,750
-2,036
-30% -$113K ﹤0.01% 1416
2024
Q4 		$380K Sell
6,786
-2,685
-28% -$148K ﹤0.01% 1203
2024
Q3 		$496K Sell
9,471
-3,156
-25% -$151K 0.01% 1104
2024
Q2 		$518K Buy
12,627
+1,524
+14% +$60.8K 0.01% 1077
2024
Q1 		$481K Sell
11,103
-7,370
-40% -$323K 0.01% 1066
2023
Q4 		$849K Buy
18,473
+4,154
+29% +$131K 0.02% 839
2023
Q3 		$328K Buy
+14,319
New +$321K 0.01% 1092

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Joel Greenblatt's RYTM Position: Q2 2026 in Review

Joel Greenblatt increased its Rhythm Pharmaceuticals (RYTM) stake by 14% in Q2 2026, buying an estimated $60.4K and bringing the position to 5,516 shares worth $612K. The position accounts for ﹤0.01% of the portfolio, ranked #1466.

Joel Greenblatt first reported a position in RYTM in Q3 2023 and has held it in 12 quarters since. The position peaked at $849K in Q4 2023. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Joel Greenblatt held 5,516 shares of Rhythm Pharmaceuticals worth $612K as of Q2 2026.
  • Joel Greenblatt bought 668 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $60.4K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1466 holding.
  • Joel Greenblatt first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Joel Greenblatt's Rhythm Pharmaceuticals position peaked at $849K in Q4 2023.
  • 300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.